30
Jul

Sanofi and Regeneron just stole a march on Amgen in the race to get their PCSK9 cardio drug through the FDA and onto the market. The two companies revealed Wednesday evening that they had picked up a priority review voucher BioMarin had won for a recent rare disease drug approval, paying $67.5 million for the regulatory shortcut. They’ll split the cost and share in the benefit, shaving four months off the regulatory review time for alirocumab.

…read more

Source: Sanofi, Regeneron pay $67.5M for a regulatory shortcut in blockbuster PCSK9 race with Amgen

    

0 No comments